Sign In
Buy OCX
$3.20
+0 (+0%)
At Close: Sep 16, 2025
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
04:05pm, Monday, 24'th Mar 2025
IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its four
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
04:05pm, Monday, 24'th Mar 2025
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
04:05pm, Tuesday, 18'th Mar 2025
IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
04:01pm, Tuesday, 18'th Mar 2025
IRVINE, Calif., March 18, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial resu
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
08:30am, Tuesday, 11'th Feb 2025
IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
08:29am, Tuesday, 11'th Feb 2025
IRVINE, Calif., Feb. 11, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Finan
Oncocyte Prices $29.1 Million Equity Offering
08:30am, Monday, 10'th Feb 2025
IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements
Oncocyte Prices $29.1 Million Equity Offering
08:30am, Monday, 10'th Feb 2025
Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 20
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
08:30am, Wednesday, 08'th Jan 2025
Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business develo
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer
08:26am, Wednesday, 08'th Jan 2025
Irvine, Calif., Jan. 8, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Me
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
04:05pm, Monday, 06'th Jan 2025
Medicare coverage expanded following study showing that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (D
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney
04:00pm, Monday, 06'th Jan 2025
Irvine, Calif., January 6, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a leader in diagnostic technology, today announced a significant milestone in the advancement of patient care for
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
04:05pm, Monday, 09'th Dec 2024
January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Exec
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
04:05pm, Monday, 09'th Dec 2024
IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial O
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
07:55am, Friday, 06'th Dec 2024
IRVINE, Calif., Dec. 04, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ ass
